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Fig. 1 – Megakaryocytes in essential thrombocythaemia, bone marrow
aspirate smear (x100). 
Table 1 – General characteristics for the PN-MPNs cases (n=121) and 
control population (n=280).
Table 2 – ORs (95% CI) for polymorphism and PN-MPNs association.
Methods
Concerning PN-MPNs susceptibility, evaluate the role of base excision repair and apoptotic genes.
Case-control study in 121 Caucasian Portuguese patients (73 with ET, 35 with PV and 13 with PMF) and 280 matched controls.
Most of the patients were diagnosed and are followed by some of the elements of this working group.
Apoptosis - rs2227309 and rs2227310 (CASP7), rs1045485 and rs1035142 (CASP8), rs2308950, rs1820204 and rs1052571 (CASP9)
and rs13006529 (CASP10)
BER - rs1799782 and rs25487 (XRCC1), rs1052133 (OGG1), rs1136410 (PARP1), rs13428 and rs1050112 (PARP4), rs1130409
(APEX1) and rs3219489 (MUTYH)
All SNPs under study were genotyped using real-time PCR (RT-PCR 7300 Applied Biosystem), through TaqMan® SNP genotyping
assays (Life Technology), according to manufacturer instructions.
Differences in genotype frequency, smoking status, age class, gender, therapeutic and pathology distributions between patients
and controls were evaluated using SPSS 22.0 (SPSS Inc.).
Results
Alcohol consumption is associated with PN-MPNs risk (Table1).
Apoptosis – When considering ET, a consistent increase in overall PN-MPNs risk was observed for rs1820104 (CASP9)
(Table1 and 2).
BER – When considering men with PV, a consistent increase in overall PN-MPNs risk was observed for the presence
of at least one variant allele carriers for rs3219489 (MUTYH) (Table 1 and 2).
When considering women with ET, a protective effect in overall PN-MPNs risk was observed for the presence of at
least one variant allele carriers for rs25487 (XRCC1_399) (Table 1 and 2).
PARP4_13 is in linkage disequilibrium with PARP4_01.
No significant difference was found between the case and control groups concerning age distribution, gender,
smoking habits or genotype frequencies (Table 1). No significant change in crude or adjusted OR was observed for
any of the other genotypes considered.
Conclusions
It seems that alcohol consumption increases the risk for PN-MPNs development.
Apoptosis – In ET, our results reveal a significant involvement of rs1820104 (CASP9) polymorphism on the individually
susceptibility towards PN-MPNs.
There are studies that show modifications in the expression of molecules that participate in the regulation of
apoptosis, indicating that this mechanism is involved in the pathophysiology of these diseases.
BER – Our results suggest that polymorphisms such as rs3219489 (MUTYH) and rs25487 (XRCC1_399) may influence
PN-MPNs susceptibility, when considering pathology and gender stratification.
JAK2V617F was not statistically analyzed yet, due to the lack of information about its results.
Larger studies are required to confirm these results and to provide conclusive evidence of association between these
and other variants and PN-MPNs and therapeutic response.
Identification of the main molecules that are altered in MPNs allows the development of drugs more directly targeted
to the pathophysiology of the disease, with high efficacy, fewer adverse effects, contributing to compliance of the
patients with treatments.
Future projects
We also intend to study 90 samples from PN-MPN patients treated with hydroxyurea, that are under clinical follow
up, to assess the association of selected critical DNA repair genes (e.g. base excision repair, homologous
recombination and non-homologous end joining pathways) with therapeutic efficacy and prognosis.
In the future, these new data may contribute to a more rational and efficient choice of therapeutic strategies to be
adopted in the treatment of PN-NMPs.
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Background
The Philadelphia-chromosome negative myeloproliferative neoplasms (PN-MPN) (Fig 1), which include Polycythemia vera (PV), Essential
Thrombocythemia (ET) and Primary Myelofibrosis (PMF), are associated with several somatic mutations, alone or in association with JAK2 V617F.
Several Single Nucleotide Polymorphisms (SNPs) have been identified, in other malignant disorders, that may influence DNA repair capacity and
apoptosis mechanisms which, in turn, increase genetic predisposition to disease and determine therapeutic response. Moreover, in PN-MPNs,
despite the development of more efficient drugs in the last years, some patients with PN-MPNs still evolve to myelodysplasia, myelofibrosis and
acute leukaemia, conditions more difficult to treat.
Characteristics Cases, n (%) Controls, n (%) P value
Gender
Male
Female
55 (45.8)
65 (54.2)
132 (47.1)
148 (52.9)
0.8
Age a, b
30-49
50-69
≥70
16 (13.2)
47 (38.8)
58 (47.9)
43 (15.4)
106 (37.9)
131 (46.8)
0.9
Smoking habits
Never
Current
93 (76.9)
28 (23.1)
212 (76.0)
67 (24.0)
0.9
Alcohol habits
Never
Social
Regular
92 (76.0)
20 (16.5)
9 (7.4)
190 (68.1)
25 (9.0)
64 (22.9)
<0.0001
APOPTOSIS
CASP9 (Phe136Leu; rs1820204) 0.2
Leu/Leu
Leu/Phe
Phe/Phe
28 (23.1)
66 (54.5)
27 (22.3)
87 (31.3)
128 (46.0)
63 (22.7)
BER
MUTYH (Gln335His; rs3219489) 0.7
His/His
Gln/His
Gln/Gln
61 (50.4)
47 (38.8)
13 (10.7) 
142 (51.3)
112 (40.4)
23 (8.3)
XRCC1_399 (Gln399Arg ; rs25487) 0.8
Arg/Arg
Arg/Gln
Gln/Gln
52 (43.0)
54 (44.6) 
15 (12.4)
113 (40.8)
134 (48.4) 
30 (10.8)
a Age of diagnosis for cases
b Age of control population at the time of diagnosis for the matched case
Foto
tipo pass,
of presenter
Pathology 
stratification
n SNP OR crude
(95% CI)
P value
APOPTOSIS
ET 73 CASP9 (Phe136Leu; rs1820204)
Leu/Leua
Leu/Phe
Phe/Phe
1 (Reference)
2.3 (1.2-4.7)
2.3 (1.0-5.0)
0.018
0.038
BER
Male 
with PV
19 MUTYH (Gln335His; rs3219489)
His/Hisa
His/Gln or Gln/Gln
1 (Reference)
3.1 (1.0-9.0) 0.041
Female
with ET
40 XRCC1_399 (Gln399Arg; rs25487)
Arg/Arga
Arg/Gln or Gln/Gln
1 (Reference)
0.5 (0.2-1.0) 0.043
a The genotype considered as reference class
